Salarius Pharmaceuticals Inc (SLRX)

$0.83 -0.06 (-6.84%)
Market Cap 1.89M
Revenue (ttm) 0.00
Net Income (ttm) -5.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 92,700
Avg Vol 1,438,414
Day's Range N/A - N/A
Shares Out 2.13M
Stochastic %K 9%
Beta 0.44
Analysts Strong Buy
Price Target $26.00

Company Profile

Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The...

Industry: Biotechnology
Sector: Healthcare
Phone: (713) 913-5608
Address:
2450 Holcombe Blvd., Suite X, Houston, United States
The_Baba_Yaga
The_Baba_Yaga Jul. 7 at 6:41 PM
$SLRX All depends on who they sell their soul to. Could it squeeze? Yeah, but again depends on what the company does. It’s risky but could work. They need 2.5M equity line fulfilled and min bid requirement as well.
0 · Reply
PaulLaurent
PaulLaurent Jul. 6 at 5:51 PM
💸📛 Highest Borrow Fee Stocks 📛💸 $SLRX $FOXX $DGNX $OGEN $NIVF
0 · Reply
PaulLaurent
PaulLaurent Jul. 1 at 7:50 PM
💸📛 Highest Borrow Fee Stocks $OP $ASTI $FOXX $SLRX $NXTT
1 · Reply
PaulLaurent
PaulLaurent Jun. 30 at 7:03 PM
💸📛 Highest Borrow Fee Stocks $OP $FOXX $SLRX $NXTT $ASTI
1 · Reply
giorga
giorga Jun. 30 at 4:34 AM
$SLRX Compliance deadlines: • Early July 2025 must restore stockholders’ equity to ≥ $2.5M. • Early August 2025 must achieve a closing price ≥ $1.00 for 10 consecutive trading days. RS: Authorised by shareholders (May 2025) 1-for-4 to 1-for-40 at any time.
0 · Reply
Xunefox
Xunefox Jun. 28 at 3:43 AM
$SLRX so what does rhis mean they didnt make 10 days over $1?
0 · Reply
zoun987
zoun987 Jun. 27 at 7:44 AM
$SLRX
0 · Reply
RonBoy3
RonBoy3 Jun. 26 at 2:22 PM
$SLRX And on #7 they are working hard to try to close it below a dollar today…!
0 · Reply
RonBoy3
RonBoy3 Jun. 25 at 7:20 PM
$SLRX Of the seven stocks that I’m watching including Tesla are in the red today. These market makers are having a field day with everyone….!
0 · Reply
PenkeTrading
PenkeTrading Jun. 25 at 12:38 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Salarius Pharmaceuticals Inc. Is that bullish or bearish? $SLRX #Salarius #RsiOverbought #NASDAQ
0 · Reply
Latest News on SLRX
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Apr 16, 2025, 8:00 AM EDT - 2 months ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Feb 3, 2025, 8:00 AM EST - 5 months ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Jan 13, 2025, 2:12 PM EST - 6 months ago

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Jan 3, 2024, 8:30 AM EST - 1 year ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023, 8:30 AM EST - 1 year ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023, 8:17 AM EDT - 2 years ago

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 9, 2023, 8:00 AM EDT - 2 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

May 1, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Apr 4, 2023, 4:02 PM EDT - 2 years ago

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 27, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 15, 2023, 11:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Feb 16, 2023, 8:30 AM EST - 2 years ago

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 27, 2023, 8:30 AM EST - 2 years ago

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 19, 2023, 8:30 AM EST - 2 years ago

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Dec 13, 2022, 8:01 AM EST - 2 years ago

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Dec 13, 2022, 8:00 AM EST - 2 years ago

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Dec 1, 2022, 8:00 AM EST - 2 years ago

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 8:30 AM EST - 2 years ago

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Nov 3, 2022, 9:57 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 27, 2022, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 19, 2022, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Oct 18, 2022, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Oct 14, 2022, 8:43 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Sep 20, 2022, 12:00 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing's Sarcoma and FET-Rearranged Sarcomas

Aug 22, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing's Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript

Aug 8, 2022, 2:54 PM EDT - 3 years ago

Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 8, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Aug 4, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Aug 2, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Jul 29, 2022, 9:15 AM EDT - 3 years ago

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

Jun 9, 2022, 7:33 AM EDT - 3 years ago

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

May 18, 2022, 4:10 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2022 Results - Earnings Call Transcript

May 12, 2022, 9:32 PM EDT - 3 years ago

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2022 Results - Earnings Call Transcript

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

May 12, 2022, 4:05 PM EDT - 3 years ago

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

May 11, 2022, 4:05 PM EDT - 3 years ago

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

May 5, 2022, 7:30 AM EDT - 3 years ago

Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

Apr 22, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2021 Results - Earnings Call Transcript

Mar 10, 2022, 11:09 PM EST - 3 years ago

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2021 Results - Earnings Call Transcript

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

Mar 10, 2022, 4:05 PM EST - 3 years ago

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

The_Baba_Yaga
The_Baba_Yaga Jul. 7 at 6:41 PM
$SLRX All depends on who they sell their soul to. Could it squeeze? Yeah, but again depends on what the company does. It’s risky but could work. They need 2.5M equity line fulfilled and min bid requirement as well.
0 · Reply
PaulLaurent
PaulLaurent Jul. 6 at 5:51 PM
💸📛 Highest Borrow Fee Stocks 📛💸 $SLRX $FOXX $DGNX $OGEN $NIVF
0 · Reply
PaulLaurent
PaulLaurent Jul. 1 at 7:50 PM
💸📛 Highest Borrow Fee Stocks $OP $ASTI $FOXX $SLRX $NXTT
1 · Reply
PaulLaurent
PaulLaurent Jun. 30 at 7:03 PM
💸📛 Highest Borrow Fee Stocks $OP $FOXX $SLRX $NXTT $ASTI
1 · Reply
giorga
giorga Jun. 30 at 4:34 AM
$SLRX Compliance deadlines: • Early July 2025 must restore stockholders’ equity to ≥ $2.5M. • Early August 2025 must achieve a closing price ≥ $1.00 for 10 consecutive trading days. RS: Authorised by shareholders (May 2025) 1-for-4 to 1-for-40 at any time.
0 · Reply
Xunefox
Xunefox Jun. 28 at 3:43 AM
$SLRX so what does rhis mean they didnt make 10 days over $1?
0 · Reply
zoun987
zoun987 Jun. 27 at 7:44 AM
$SLRX
0 · Reply
RonBoy3
RonBoy3 Jun. 26 at 2:22 PM
$SLRX And on #7 they are working hard to try to close it below a dollar today…!
0 · Reply
RonBoy3
RonBoy3 Jun. 25 at 7:20 PM
$SLRX Of the seven stocks that I’m watching including Tesla are in the red today. These market makers are having a field day with everyone….!
0 · Reply
PenkeTrading
PenkeTrading Jun. 25 at 12:38 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Salarius Pharmaceuticals Inc. Is that bullish or bearish? $SLRX #Salarius #RsiOverbought #NASDAQ
0 · Reply
RonBoy3
RonBoy3 Jun. 24 at 11:15 PM
$SLRX Not too shabby everybody and that makes five days in a row closing above a dollar. Looking good.
0 · Reply
Here4cabbage
Here4cabbage Jun. 24 at 10:15 PM
$SLRX they have 6 months to stay about $1. Insiders may pump above 2. Hopefully. I'm not saying it will though
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 24 at 3:35 PM
$SLRX With clinical trials ongoing and a transformative merger in motion, Salarius is emerging as a multi-platform force in precision medicine. https://biotechhealthx.com/biotech-news/wall-street-is-turning-bullish-on-salarius-pharmaceuticals-slrx/
0 · Reply
RonBoy3
RonBoy3 Jun. 24 at 1:36 PM
$SLRX In all honesty, I exited late yesterday afternoon around $1.20 but I will continue watching closely. If they make it to the eighth or ninth day staying above a dollar… I will definitely jump back in…Woohoo…!
0 · Reply
RonBoy3
RonBoy3 Jun. 24 at 9:28 AM
$SLRX Not too bad for the last for trading days to remain above the $1 mark. Let’s work on the next six days to do the same…!
0 · Reply
RonBoy3
RonBoy3 Jun. 23 at 9:58 PM
$SLRX Tomorrow Will be day number five above a dollar…?
0 · Reply
chivas1234
chivas1234 Jun. 23 at 3:47 PM
$SLRX solid trend still. 4 HR. RSI rising, MACD curl soon, above VWAP
0 · Reply
RonBoy3
RonBoy3 Jun. 23 at 1:41 PM
$SLRX Well we are in the fourth day of our attempt to stay above a dollar. It’s not going to be easy but we need to do it for at least 10 days to produce positive results…!
0 · Reply
IndicatorGator
IndicatorGator Jun. 20 at 8:10 PM
This Week’s Results. Short 4 Day Week. -20 Opportunities for profit. 5 per day average. -12 Opportunities for 50% or more -4 Opportunities for 90% or more -Follow and Subscribe for Alerts, Watchlist and PROFITS. -16 June: BATL $2.72 to $6.33 (132%) SRM: $5.06 to $10.82 (113%) STAK $6.01 to $9.72 (61%) SVRE $4.51 to $6.63 (47%) AIRO $30 to 37.93 (26%) OP: $3.76 to $4.38 (16%) SONM $2.33 to $2.69 (15%) -17 June: HUSA: $11.30 to $22.20 (96%) $SLRX: $1.11 to $2.15 (93%) $CERO: $14.51 to $26.99 (86%) $ACXP: .71 to $1.16 (63%) PCSA: .51 to .78 (53%) -18 June: $LSE $7 to $12 (71%) $PTLE .36 to .61 (69%) RELI $2.56 to $3.91 (52%) APVO $9.37 to $$13.11 (42%) RYDE: .51 to .57 (11%) -19 June: Holiday -20 June: WHLR $6.26 to $10.05 (60%) PCSA .26 to .32 (23%) LUCY $4.01 to 4.96 (23%)
0 · Reply
Mervolo
Mervolo Jun. 20 at 7:25 PM
$LUCY if we can stay around this area for monday that would be GREAT. $HCTI lolz oh man. Still green but not as green as i was. $SLRX $INLF super chillin👍👍👍 $MITQ a nickel’s a nickel 👌
0 · Reply
RonBoy3
RonBoy3 Jun. 20 at 7:07 PM
$SLRX We have power hour and after hours trading ahead. It could get quite interesting…!
0 · Reply
Mervolo
Mervolo Jun. 20 at 6:29 PM
$LUCY whelp, i guess it s beer time! Man, lolz, added more at 3,90s but i guessni shoulda waited a bit more. Oh wells, goal post still 10 plus so 🤞🤞🤞🤞. If 3,25 hits, adding more. Otherwise still waitng for rip face off reversal. $HCTI holding up super nicely so for a fri🙌 Averaged up again so don t mind holding $MITQ man, those ,85s came in clutch! Was annoyed when it dipped under ,80 but : “stocks go up! Stocks go down!” $SLRX $INLF baby positions but curious.
0 · Reply